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Nuclear factor κB (NF-κB) is a common transcription fac-
tor regulating expression of multiple genes relevant for
immune reactions. It may by activated by numerous stim-
uli and a number of data have indicated a relationship
between its activity and intracellular concentration of
cGMP. Increased levels of the nucleotide have been shown
to affect expression of TNFα, IL-1, IL-6 and NOS2 in vari-
ous immune cells. Particularly, cGMP has been shown to
affect several important functions of cells belonging to a
monocyte/macrophage lineage. Recently, we reported
that in freshly isolated human peripheral blood mononu-
clear cells (PBMC) the NF-κB activity was modulated
through a cGMP-dependent pathway. The aim of this
study was to determine whether and how cGMP may
affect an activity of NF-κB in human CD14 monocytes.
They express soluble guanylyl cyclase (sGC) as well as
cGMP-dependent protein kinase I (PKG I). We show that
in this cells nitric oxide (NO) stimulates the NF-κB activ-
ity at low and inhibits it at high doses. This effect is mim-
icked by membrane-permeable analogues of cGMP. Using
specific inhibitors, we also show that stimulatory effect of
NO/cGMP on the NF-κB activity is mediated by PKG I.
This observation is additionally supported by the fact that
stimulatory effect of NO disappears in cultured cells lack-
ing PKG I. Therefore, our results show that at least some
reported effects of NO/cGMP on monocytic cells directly
involve PKG I and NF-κB.
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